{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:07:01Z","timestamp":1789704421920,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the long-term prognosis for patients with iris melanomas and compare it with the prognosis for small choroidal melanomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective observational case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients treated for iris melanomas at a single referral institution between January 1st 1986 and January 1st 2016 were included. Patients treated for small choroidal melanomas during the same period were included for comparison. The cumulative incidence of melanoma-related mortality was calculated. Patient and tumor characteristics and size-adjusted hazard ratio (HR) for melanoma-related mortality were compared between iris and small choroidal melanomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-five iris melanomas and 268 small choroidal melanomas were included. Twenty-four iris melanomas (53%) had been treated with local resection, 12 (27%) with Ruthenium-106 brachytherapy, 7 (16%) with enucleation and 2 (4%) with proton beam irradiation. Twenty-one (68%), 7 (16%) and 2 (4%) of the iris melanomas were of the spindle, mixed and epithelioid cell types, respectively. Twenty-three patients had deceased before the end of follow-up. Median follow-up for the 22 survivors was 13.3\u2009years (SD 9.4). Patients with iris melanomas were more often asymptomatic at presentation and had a trend towards significantly lower age (59 versus 63\u2009years, Student\u2019s T-tests\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.057). Further, iris melanomas had significantly smaller basal diameter (5.8 versus 8.0\u2009mm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and tumor volume (79\u2009mm\n                      <jats:sup>3<\/jats:sup>\n                      versus 93\u2009mm mm\n                      <jats:sup>3<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) but greater thickness (3.0 versus 2.5\u2009mm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The cumulative incidence of iris melanoma-related mortality was 5% at 5\u2009years after diagnosis, and 8% at 10, 15 and 20\u2009years. The incidence was not significantly different to small choroidal melanomas (Wilcoxon\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.46). In multivariate Cox regression with tumor diameter and thickness as covariates, patients with choroidal melanomas did not have increased HR for melanoma-related mortality (HR 2.2, 95% CI 0.5\u20139.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.29). Similarly, there were no significant survival differences in matched subgroups (Wilcoxon\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.82).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There are no survival differences between iris and choroidal melanomas when adjusting for tumor size. The reason for the relatively favorable prognosis of iris melanomas compared to melanomas of the choroid and ciliary body is likely that they are diagnosed at a smaller size.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-09002-0","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T12:03:43Z","timestamp":1637755423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter"],"prefix":"10.1186","volume":"21","author":[{"given":"Shiva","family":"Sabazade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Herrspiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"St\u00e5lhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"8","key":"9002_CR1","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","volume":"83","author":"AE Chang","year":"1998","unstructured":"Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664\u201378.","journal-title":"Cancer"},{"issue":"6","key":"9002_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000497186","volume":"5","author":"G Stalhammar","year":"2019","unstructured":"Stalhammar G, See TR, Fili M, Seregard S. No gender differences in long-term survival after brachytherapy of 1,541 patients with uveal melanoma. Ocul Oncol Pathol. 2019;5(6):432\u20139.","journal-title":"Ocul Oncol Pathol"},{"issue":"3","key":"9002_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/sj.bjc.6605765","volume":"103","author":"B Damato","year":"2010","unstructured":"Damato B. Does ocular treatment of uveal melanoma influence survival? Br J Cancer. 2010;103(3):285.","journal-title":"Br J Cancer"},{"issue":"1","key":"9002_CR4","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41598-021-88390-6","volume":"11","author":"OE Uner","year":"2021","unstructured":"Uner OE, See TRO, Szalai E, Grossniklaus HE, Stalhammar G. Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep. 2021;11(1):8923.","journal-title":"Sci Rep"},{"issue":"1","key":"9002_CR5","doi-asserted-by":"publisher","first-page":"11297","DOI":"10.1038\/s41598-020-68232-7","volume":"10","author":"G Stalhammar","year":"2020","unstructured":"Stalhammar G. Forty-year prognosis after plaque brachytherapy of uveal melanoma. Sci Rep. 2020;10(1):11297.","journal-title":"Sci Rep"},{"issue":"11","key":"9002_CR6","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"9002_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala ES, Hernberg M, Kivela TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561\u20138.","journal-title":"Melanoma Res"},{"issue":"2","key":"9002_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32(2):204\u2013220.e215.","journal-title":"Cancer Cell"},{"issue":"6","key":"9002_CR9","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/cam4.2167","volume":"8","author":"G St\u00e5lhammar","year":"2019","unstructured":"St\u00e5lhammar G, Seregard S, Grossniklaus HE. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma. Cancer Med. 2019;8(6):2784\u201392.","journal-title":"Cancer Med"},{"issue":"22","key":"9002_CR10","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, et al. Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869\u201378.","journal-title":"Clin Cancer Res"},{"key":"9002_CR11","volume-title":"Eugene Wolff's anatomy of the eye and orbit : including the central connexions, development, and comparative anatomy of the visual apparatus","author":"E Wolff","year":"1976","unstructured":"Wolff E, Warwick R. Eugene Wolff's anatomy of the eye and orbit : including the central connexions, development, and comparative anatomy of the visual apparatus. 7th ed. Philadelphia: Saunders; 1976.","edition":"7"},{"issue":"8","key":"9002_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989\u201398.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"9002_CR13","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","volume":"11","author":"PA Johansson","year":"2020","unstructured":"Johansson PA, Brooks K, Newell F, Palmer JM, Wilmott JS, Pritchard AL, et al. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nat Commun. 2020;11(1):2408.","journal-title":"Nat Commun"},{"issue":"1","key":"9002_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"9002_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ophtha.2017.10.009","volume":"125","author":"J Thariat","year":"2018","unstructured":"Thariat J, Rahmi A, Salleron J, Mosci C, Butet B, Maschi C, et al. Proton beam therapy for iris melanomas in 107 patients. Ophthalmology. 2018;125(4):606\u201314.","journal-title":"Ophthalmology"},{"issue":"2","key":"9002_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0046-8177(82)80116-0","volume":"13","author":"IW McLean","year":"1982","unstructured":"McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13(2):123.","journal-title":"Hum Pathol"},{"issue":"7","key":"9002_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0161-6420(87)33537-7","volume":"94","author":"CL Shields","year":"1987","unstructured":"Shields CL, Shields JA, Shields MB, Augsburger JJ. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology. 1987;94(7):839\u201346.","journal-title":"Ophthalmology"},{"issue":"2","key":"9002_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (London, England). 2017;31(2):241.","journal-title":"Eye (London, England)"},{"issue":"6","key":"9002_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00417-019-04296-0","volume":"257","author":"MM Oxenreiter","year":"2019","unstructured":"Oxenreiter MM, Lane AM, Jain P, Kim IK, Gragoudas ES. Conservative management of suspicious melanocytic lesions of the iris. Graefes Arch Clin Exp Ophthalmol. 2019;257(6):1319\u201324.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"9002_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaapos.2011.10.012","volume":"16","author":"CL Shields","year":"2012","unstructured":"Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: features and prognosis in 317 children and adults. J AAPOS. 2012;16(1):10\u20136.","journal-title":"J AAPOS"},{"issue":"5","key":"9002_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/aos.13668","volume":"96","author":"TS Arnljots","year":"2018","unstructured":"Arnljots TS, Al-Sharbaty Z, Lardner E, All-Eriksson C, Seregard S, St\u00e5lhammar G. Tumour thickness, diameter, area or volume? The prognostic significance of conventional versus digital image analysis-based size estimation methods in uveal melanoma. Acta Ophthalmol. 2018;96(5):510\u20138.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"9002_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/archopht.1992.01080140101036","volume":"110","author":"M Diener-West","year":"1992","unstructured":"Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110(2):245\u201350.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"9002_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0039-6257(96)80024-5","volume":"41","author":"CM Mooy","year":"1996","unstructured":"Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996;41(3):215\u201328.","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"9002_CR24","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/eye.2009.235","volume":"23","author":"B Damato","year":"2009","unstructured":"Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye (Lond). 2009;23(12):2152\u201360 quiz 2161-2152.","journal-title":"Eye (Lond)"},{"issue":"C","key":"9002_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","volume":"53","author":"S Ugurel","year":"2016","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer. 2016;53(C):125\u201334.","journal-title":"Eur J Cancer"},{"issue":"4","key":"9002_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/bjophthalmol-2020-316498","volume":"105","author":"C Herrspiegel","year":"2021","unstructured":"Herrspiegel C, Kvanta A, Lardner E, Ramskold Cabaca L, Wells J, Bartuma K, et al. Nuclear expression of BAP-1 in transvitreal incisional biopsies and subsequent enucleation of eyes with posterior choroidal melanoma. Br J Ophthalmol. 2021;105(4):582\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"9002_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-017-02428-w","volume":"9","author":"MG Field","year":"2018","unstructured":"Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, et al. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun. 2018;9(1):116.","journal-title":"Nat Commun"},{"key":"9002_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ajo.2019.01.031","volume":"202","author":"S Jouhi","year":"2019","unstructured":"Jouhi S, Jager MJ, de Geus SJR, Desjardins L, Eide NA, Grange JD, et al. The small fatal choroidal melanoma study. A survey by the European Ophthalmic Oncology Group. Am J Ophthalmol. 2019;202:100\u20138.","journal-title":"Am J Ophthalmol"},{"key":"9002_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.exer.2019.04.001","volume":"182","author":"MC Herwig-Carl","year":"2019","unstructured":"Herwig-Carl MC, Sharma A, Holler T, Holz FG, Schlitter AM, Loeffler KU. Spatial intratumor heterogeneity in uveal melanoma: tumor cell subtypes with a presumed invasive potential exhibit a particular epigenetic staining reaction. Exp Eye Res. 2019;182:175\u201381.","journal-title":"Exp Eye Res"},{"key":"9002_CR30","doi-asserted-by":"crossref","unstructured":"Stalhammar G, Grossniklaus HE. Intratumor heterogeneity in uveal melanoma BAP-1 expression. Cancers (Basel). 2021;13(5):1-15","DOI":"10.3390\/cancers13051143"},{"issue":"8","key":"9002_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","volume":"133","author":"MP Gupta","year":"2015","unstructured":"Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES, et al. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol. 2015;133(8):881\u20137.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"9002_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1167\/iovs.02-0159","volume":"44","author":"AG Scholes","year":"2003","unstructured":"Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003;44(3):1008\u201311.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"9002_CR33","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/bjc.2012.54","volume":"106","author":"S Thomas","year":"2012","unstructured":"Thomas S, Putter C, Weber S, Bornfeld N, Lohmann DR, Zeschnigk M. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. Br J Cancer. 2012;106(6):1171\u20136.","journal-title":"Br J Cancer"},{"issue":"1","key":"9002_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0002-9394(02)02270-5","volume":"136","author":"BR Straatsma","year":"2003","unstructured":"Straatsma BR, Diener-West M, Caldwell R, Engstrom RE, Collaborative Ocular Melanoma Study G. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003;136(1):47-54\u00a0","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"9002_CR35","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/archopht.1993.01090100090033","volume":"111","author":"JJ Augsburger","year":"1993","unstructured":"Augsburger JJ, Vrabec TR. Impact of delayed treatment in growing posterior uveal melanomas. Arch Ophthalmol. 1993;111(10):1382\u20136.","journal-title":"Arch Ophthalmol"},{"key":"9002_CR36","doi-asserted-by":"crossref","unstructured":"Fili M, Seregard S, Stalhammar G. Presenting symptoms are associated with uveal melanoma-related death. Ophthalmology. 2021;128(7):1107-9.","DOI":"10.1016\/j.ophtha.2020.11.023"}],"updated-by":[{"DOI":"10.1186\/s12885-021-09167-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T21:20:31Z","timestamp":1699824031000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9002"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09002-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-882651\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-021-09167-8","URL":"https:\/\/doi.org\/10.1186\/s12885-021-09167-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Swedish Ethical Review Authority (reference 2020-02835). The experiment protocol for involving human data was in accordance with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"According to the approved protocol, the requirement for written informed consent was waived because this was a retrospective study that did not affect treatment or follow-up of the patients. Further, all patient data had been previously compiled in our cancer registry and no new data collection was performed. No new tissues were collected, sectioned, stained or otherwise processed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflicting relationship exists for any author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1270"}}